initiated clinical trials evaluating the efficacy of these novel SSA in patients with CD, with the aim to lower circulating ACTH and cortisol levels by targeting multiple ssts on the corticotropic adenoma cells. In this minireview, the effects of SS in the regulation of normal and tumoral ACTH secretion, the role of sst subtypes involved herein, as well as the potentials of novel SSA in the treatment of patients with recurrent or persisting CD are discussed.
Introduction
Somatostatin (SS) was originally characterized as a hypothalamic peptide with a direct inhibitory activity on the secretion of growth hormone (GH) by the anterior pituitary gland [1] . Since this original discovery, numerous studies have established that SS exists in two molecular forms in the circulation, i.e. a 14-and a 28-amino acid cyclic peptide, named SS-14 and SS-28, respectively. Both peptides have a widespread biological activity due to the presence of SS receptors (sst) in many organ systems, including the brain, the pituitary gland, the gastrointestinal tract, pancreas and adrenals [2, 3] . ssts are seventransmembrane receptors that are coupled to G-proteins and of which five subtypes, named sst 1 , sst 2 , sst 3 , sst 4 and sst 5 , have been identified. On the basis of structural and pharmacological characteristics, two subclasses have been identified. To one class of sst, consisting of sst 2 , sst 3 and sst 5 , structural SS analogs (SSA), such as octreotide and lanreotide, bind with high affinity, whereas these SSA do not bind to the other class of sst, consisting of sst 1 and sst 4 ( table 1 ) [4] . Among the multiple physiological effects of SS is its potent inhibitory effect on pituitary hormone secretion [2, 3] . SS is considered as a physiological regulator of GH secretion. In vitro, the peptide inhibits the secretion of GH, prolactin (PRL), thyroid stimulating hormone (TSH), as well as adrenocorticotropin hormone (ACTH) by rat anterior pituitary cells, although its effects are strongly influenced by the respective physiological feedback hormones [5] . In human fetal pituitary cell cultures, SS inhibits the secretion of GH, TSH and PRL, whereas the release of ACTH and luteinizing hormone (LH) is only modestly influenced [6] . The effects of SS on normal and tumoral ACTH secretion are strongly regulated by glucocorticoids, representing the physiological feedback system [5] .
Role of Somatostatin Receptors in Normal Corticotropic Cells
In normal rat corticotropes, all five sst colocalize with ACTH-expressing cells [7] . In another study, it was demonstrated that sst 5 mRNA is expressed in 38% of corticotropes, whereas the expression of sst 2 mRNA is found in only 3% of the corticotropic cell population [8] . By immunohistochemistry, ! 60% and 10-20% of rat corticotropic cells express detectable sst 2A and sst 5 at the protein level, respectively [9] . In vitro, SS does not inhibit basal and CRH-induced ACTH release by normal rat anterior pituitary cells [10, 11] , whereas CRH-and vasopressininduced ACTH release is inhibited in cultured pituitary cells from long-term adrenalectomized rats [12] . In serum-deprived or in rat pituitary cells pretreated with the glucocorticoid receptor-blocking compound RU-38486 in vitro, SS inhibits CRH-stimulated ACTH secretion, but not in serum cultured cells. Moreover, pretreatment with dexamethasone abolished the inhibitory effect of SS on ACTH release [5] . Therefore, it can be concluded that SS is able to inhibit CRH-induced ACTH secretion by rat pituitary cells in vitro, but primarily in the absence of glucocorticoids.
In humans, systemic SS infusion does not inhibit basal or stimulated ACTH secretion [13] [14] [15] . On the other hand, in patients with adrenal insufficiency, SS infusion lowers circulating ACTH and cortisol levels [16] . These latter data again suggest the importance of the endogenous cortisol level in the regulation of the inhibitory effects of SS on ACTH secretion by the anterior pituitary gland. In vivo evidence in rats shows the importance of both sst 2 and sst 5 receptors in the regulation of ACTH secretion. A 1-hour pretreatment of rats with 10 g/kg pasireotide (targeting sst 2 , sst 3 and sst 5 receptors) inhibited circulating ACTH and corticosterone levels by 51 and 27%, respectively, whereas octreotide (sst 2 -preferring SSA) was significantly less potent (34% and no inhibition, respectively) at this dosage [17] . These data suggest that the combined activation of both sst 2 and sst 5 receptors in corticotropic cells results in a more potent suppression of ACTH secretion compared with the selective targeting of sst 2 alone.
In conclusion, endogenous glucocorticoid levels modulate the effects of SS on ACTH secretion by normal pituitary corticotropes. SS has an inhibitory effect on pituitary ACTH secretion, particularly when cortisol levels are low. 
Role of Somatostatin Receptors in Corticotropic Adenoma Cells
Already in 1981, Richardson and Schonbrunn [18] showed the presence of SS-binding sites in the ACTHsecreting AtT20/D16V mouse corticotropic tumor cell line and demonstrated inhibition of ACTH secretion by SS in vitro [18] . Since the cloning and characterization of the five sst, also the expression of these sst subtypes in human corticotropic adenomas has been evaluated. Human corticotropic adenomas show a predominant expression of sst 5 mRNA, whereas the majority of adenomas express sst 2 mRNA as well. Compared with sst 2 mRNA, sst 5 mRNA expression has been reported to be approximately 5-to 10-fold higher [19] [20] [21] [22] [23] . Limited studies have evaluated the expression of sst 2 and sst 5 receptors at the protein level. Batista et al. [19] showed that sst 5 had the highest immunohistochemistry score, compared with sst 1 , sst 2 , sst 3 and sst 4 protein expression, in 83% of a series of 13 corticotropic adenomas, while in another small series of three corticotropic adenomas, Hassaneen et al. [24] showed an absence of sst 5 immunostaining. The reason for these discordant results is unclear, but may be the result of the use of different antibodies. Coexpression of sst 1 receptors has been reported in only a proportion of corticotropic adenomas [20] [21] [22] [23] . Interestingly, in silent corticotropic adenomas a considerable higher sst 1 and sst 2 , but lower sst 5 mRNA expression was found, compared with corticotropic adenomas causing Cushing's disease (CD) [20] .
In primary cultures of corticotropic adenomas the universal SSA pasireotide (high sst 2 -, sst 3 -and sst 5 -binding affinity) was significantly more potent in inhibiting ACTH secretion, compared with the sst 2 -preferring SSA octreotide [22] . Following a 72-h incubation, octreotide (10 n M ) inhibited ACTH secretion by 28% in only 1 of 5 cultures, whereas pasireotide (10 n M ) induced significant suppression of ACTH secretion in 3 of 5 cultures (30-40% suppression) [22] . Moreover, Batista et al. [19] demonstrated significant suppression of ACTH secretion in 5 of 6 cultures (23-56% suppression). In AtT20 corticotropic adenoma cells, both pasireotide, as well as sst 5 -selective SSA were more potent inhibitors of basal and CRH-induced ACTH secretion, compared with sst 2 -preferring SSA ( fig. 1 ) [22, 25] . sion of ACTH release only at 100 n M . These effects clearly indicate that ACTH secretion is inhibited in a 'sst 5 -like' fashion, in agreement with the binding affinities of pasireotide and octreotide to sst 2 and sst 5 ( table 1 ) . Recently, it was shown that sst 5 determines both the short-and long-term enhanced action of pasireotide in corticotropic tumor cells, whereas the ligand action on sst 2 is negligible. Short-term exposure to pasireotide caused prolonged signaling in terms of forskolin-or CRH-induced cAMP accumulation, in contrast to SS-14 and sst 2 -selective agonists that induced a postwithdrawal cAMP rebound [26] .
In conclusion, sst 5 receptors are expressed at a significant level in corticotropic adenomas and seem a target to lower tumoral ACTH secretion with sst 5 -preferring SSA.
Regulation of Somatostatin Receptor Expression by Glucocorticoids
The observation that SS and the sst 2 -preferring SSA octreotide do not inhibit circulating ACTH levels in patients with untreated CD [27, 28] , in combination with the inhibitory effects of SS on ACTH levels in patients with adrenal insufficiency (Addison's disease) [16] and Nelson's syndrome [27, 29] , suggests that glucocorticoids have a negative regulatory role on the expression of sst receptors, particularly sst 2 , and indicates that SS is a potent inhibitor of ACTH secretion in patients with elevated ACTH levels due to a lack in steroid feedback. Downregulation of SS-binding sites on AtT20 corticotropic tumor cells was previously shown by Schonbrunn [30] . More recently, we found that dexamethasone treatment of AtT20 cells induced a significant suppression of sst 2 mRNA expression, whereas sst 5 mRNA expression was not significantly affected [25] . Moreover, the number of binding sites for the sst 2 -preferring SSA octreotide was lowered by 72% by dexamethasone treatment, whereas the total number of binding sites for SS-14 was lowered only by 17%. These data suggest that the sst 5 protein expression, compared with sst 2 , is more resistant to downregulation by glucocorticoids. The functional consequence of this effect was further underlined by the observation that the effects of octreotide on CRH-induced ACTH secretion by AtT20 cells were abolished by dexamethasone treatment, whereas pasireotide potently suppressed CRH-induced ACTH secretion, even in the presence of 10 n M dexamethasone ( fig. 2 ) [25] .
In conclusion, sst 2 receptor expression on corticotropic adenoma cells is downregulated by glucocorticoids, whereas sst 5 receptor expression is less sensitive to this downregulation. These data may form an explanation for the low sst 2 and relatively high sst 5 expression levels in corticotropic adenomas of patients with CD. Moreover, these observations may explain the lack of efficacy of sst 2 -preferring SSA in patients with CD and suggest an enhanced potency of sst 2 -sst 5 targeting SSA on ACTH secretion by corticotropic adenomas. 
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Outlook
The observation that sst 5 receptors are expressed at significant levels in human corticotropic adenomas, together with the more important role of sst 5 , compared with sst 2 , in the regulation of tumoral ACTH secretion, has initiated clinical trials testing the efficacy of the universal SSA pasireotide in patients with CD. Promising results of a first phase II clinical study with pasireotide in CD have been recently reported [31] . On the basis of the potent inhibitory effect of glucocorticoids on sst 2 expression in corticotropic adenoma cells, it can be hypothesized that lowering of circulating cortisol levels in patients with CD results in an upregulation of sst 2 expression on the corticotropic adenoma, thereby further contributing to an ACTH-lowering effect of sst 2 -sst 5 targeting SSA. This lowering of circulating cortisol in patients with recurrent or persisting CD may be achieved with sst 2 -sst 5 targeting SSA, but also with dopamine D2 agonists, such as cabergoline, or with drugs inhibiting cortisol production at the adrenal level, such as ketoconazole. Corticotropic adenomas express D2 in about 70% of the cases [32] and cabergoline induces long-term normalization in approximately 40% of patients with CD unsuccessfully treated by surgery [33] . D2 mRNA receptor expression in corticotropic adenomas is significantly higher compared to sst 5 and sst 2 mRNA expression [21, 23] . Interestingly, unlike sst 2 , but comparable to sst 5 , D2 receptor expression seems not under the negative regulatory control by glucocorticoids [34] . We recently found that biochemical remission can be achieved in 90% of patients with CD (n = 17) with pasireotide monotherapy (29%), with combined pasireotide-cabergoline treatment (in an additional 24%) and in another 35% with triple therapy with pasireotide, cabergoline and ketoco nazole [ 35 , and this issue] . Therefore, a future approach for medical treatment of recurrent or persistent CD may involve combination therapy with drugs that have additive or potentiating effects.
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